SLS

SELLAS LIFE SCIE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.600
-0.130
-7.51%
Closed 19:59 04/01 EDT
OPEN
1.790
PREV CLOSE
1.730
HIGH
1.790
LOW
1.530
VOLUME
204.46K
TURNOVER
--
52 WEEK HIGH
61.50
52 WEEK LOW
1.600
MARKET CAP
10.75M
P/E (TTM)
-0.0738
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SLS stock price target is 8.50 with a high estimate of 9.00 and a low estimate of 8.00.

EPS

SLS News

More
  • Sellas Life Sciences up 4% on encouraging nelipepimut-S data
  • Seeking Alpha - Article · 03/18 13:58
  • SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast from Phase 2 VADIS Study
  • GlobeNewswire · 03/18 13:30
  • SLS, APRN among premarket gainers
  • Seeking Alpha - Article · 03/18 13:23
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About SLS

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
More

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.